Clinical trials: Patient With Colorectal Cancer
Colorectal Cancer, ERAS
Compliance With ERAS and Five Year Survival After Colorectal Cancer Treatment
The Enhanced Recovery after Surgery (ERAS) protocol has transformed perioperative care, representing a significant paradigm shift in managing colorectal cancer patients.
- Trial name
- NCT06342687
- Testing
- High compliance with ERAS protocol
- Where
- Poland
- Volunteers
- 468 people
- Sponsor
- Jagiellonian University
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Colorectal Cancer
A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis
Short description for lay public, include brief statement of the study hypothesis
- Trial name
- NCT01978249
- Testing
- Systemic chemotherapy, primary tumor resection (PTR)
- Where
- 12 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Yonsei University
Liver Neoplasms
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
This study will evaluate the safety and effects of vaccine treatment plus radiation to the liver in patients with solid tumors that have spread to the liver.
- Trial name
- NCT00081848
- Testing
- rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Prevention, LARS - Low Anterior Resection Syndrome
Effectiveness of Pelvic Floor Exercise to Prevent LARS (Low Anterior Resection Syndrome)
The main aim of this randomized study will be to determine the effectiveness of pelvic floor exercises on the incidence or severity of LAR syndrome in patients after mini-invasive rectal resection.
- Conditions
- Prevention, LARS - Low Anterior Resection Syndrome, Pelvic Floor Disorders, Rectal Cancer
- Trial name
- CH1 (NCT06519006)
- Testing
- Pelvic floor exercise
- Where
- Slovakia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- F. D. Roosevelt University Hospital
Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors.
- Trial name
- NCT04843033
- Testing
- SH3809 tablet
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Colorectal Cancer, Colon Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides RNF43, TOMM34, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT00677287
- Testing
- RNF43, TOMM34, VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Metastatic Colorectal Cancer
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment…
- Trial name
- NCT05694936
- Testing
- Sodium Valproate, Panitumumab, Cetuximab
- Where
- 12 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Colorectal Cancer
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
In patients in progression after oxaliplatin and irinotecan, the study FOLFIRINOX 3 proposes to evaluate the interest of modifying the standard pattern of administration of the molecule of irinotecan in order to make it more…
- Trial name
- FOLFIRINOX3 (NCT03795311)
- Testing
- FOLFIRINOX Bevacizumab
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Georges Francois Leclerc
Colorectal Cancer
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
- Trial name
- HORIZON III (NCT00384176)
- Testing
- Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX)
- Where
- 280 sites in United States, Australia and 26 more
- Volunteers
- 1,814 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Colon Cancer, Rectum Cancer
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
Efficacy of colonoscopy, colon capsule and fecal immunological test for colorectal cancer screening, in first degree relatives of patients with colorectal neoplasia: a prospective randomized study.
- Trial name
- FAMCAP (NCT02738359)
- Testing
- optical colonoscopy, colon capsule endoscopy, fecal immunological test (FIT)
- Where
- 17 sites in France
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Hôpital Edouard Herriot
Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
- Trial name
- XS-03-II201 (NCT06936527)
- Testing
- Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Rectal Cancer, Lymph Node Metastases
FDG - PET / MRI in Patients With Rectal Cancer
The combination of FDG-PET/CT and MRI at staging of rectal cancer in diagnosis is currently very little studied. The investigator have a unique opportunity to study this.
- Trial name
- RECTOPET (NCT03846882)
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Västerbotten
Colorectal Cancer
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
The aim of this study is to evaluate the activity, in terms of best response according to RECIST criteria 1.1 as assessed by the local investigator, of the ctDNA-guided retreatment with encorafenib plus cetuximab in BRAFV600E…
- Trial name
- BRICKET (NCT06578559)
- Testing
- Cetuximab, Encorafenib
- Where
- 13 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
- Trial name
- NCT03566355
- Testing
- curative proton therapy
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- National Cancer Center, Korea
Colorectal Liver Metastases, Colorectal Neoplasms
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline…
- Conditions
- Colorectal Liver Metastases, Colorectal Neoplasms, Liver Neoplasms
- Trial name
- NCT07830576
- Testing
- Multimodal Predictive Evaluation
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Anhui Provincial Hospital
Uterine Cervical Neoplasms, Endometrial Neoplasms
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
[F-18] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts.
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms
- Trial name
- NCT01717391
- Testing
- fluorothymidine F 18
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- John M. Buatti
Cancer, Lung Cancer
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular…
- Conditions
- Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer
- Trial name
- UMBRELLA (NCT06332274)
- Testing
- Tislelizumab, Blood sampling
- Where
- France
- Volunteers
- 717 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris